|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RESEARCH COMMUNICATION
1 Laboratory of Genetics, National Institute on Aging, Baltimore, Maryland 21224, USA; 2 Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA; 3 Institute for Cancer Genetics, Columbia University, New York, New York 10032, USA
| Abstract |
|---|
|
|
|---|
[Keywords: SWI/SNF; BAF; PBAF; RSC; chromatin remodeling; interferon]
Received April 15, 2005; revised version accepted May 27, 2005.
SWI/SNF complexes are evolutionarily conserved from yeast to human, and have been implicated to participate in many biological processes, such as transcriptional regulation, tumorigenesis, development, and differentiation (Vignali et al. 2000
). They can be grouped into two major subfamilies: One includes human BAF (BRG1 or hbrm-associated factor), Drosophila BAP, and yeast SWI/SNF; the other comprises human PBAF (Polybromo-associated BAF), Drosophila PBAP, and yeast RSC (Cairns et al. 1994
, 1996
; Cote et al. 1994
; Kwon et al. 1994
; Wang et al. 1996
; Papoulas et al. 1998
; Nie et al. 2000
; Xue et al. 2000
; Mohrmann et al. 2004
). These two subfamilies of complexes have similar subunit compositions, but appear to have different functions (Angus-Hill et al. 2001
; Lemon et al. 2001
). For example, human BAF and PBAF complexes share eight identical subunits, and are distinguished by the presence of only two unique subunits: BAF180 (also called Polybromo) for PBAF and BAF250a for BAF (Nie et al. 2000
; Xue et al. 2000
). Despite such similarities, only PBAF, but not BAF, is capable of facilitating ligand-dependent transcriptional activation by nuclear receptors in vitro (Lemon et al. 2001
). Whether and how these complexes selectively regulate expression of different genes in vivo remain largely unclear. Here, we present in vivo evidence that PBAF and BAF do have selectivity in regulating interferon-responsive genes. Moreover, we have identified a second specificity subunit for PBAF, termed BAF200, and demonstrated that BAF200, but not BAF180, is required for PBAF to mediate expression of an interferon-responsive gene, suggesting that BAF200 is an important targeting subunit of PBAF.
| Results and Discussion |
|---|
|
|
|---|
We and others have described purification of the two major human SWI/SNF complexes, BAF (hSWI/SNF-A) and PBAF (hSWI/SNF-B) (Kwon et al. 1994
; Wang et al. 1996
; Nie et al. 2000
; Xue et al. 2000
; Lemon et al. 2001
). These two complexes share as many as eight common subunits (BRG1, BAF170, BAF155, BAF60a, BAF57, BAF53, actin, and hSNF5/INI1), but are distinguished by the presence of two specificity subunits: BAF180 present only in PBAF, and BAF250a exclusively present in BAF (Nie et al. 2000
; Xue et al. 2000
; Lemon et al. 2001
). We also noticed the presence of a 200-kDa polypeptide, referred to as BAF200, in PBAF complex purified by antibodies against BRG1, BAF180, and hSNF5 (Wang et al. 1996
; Xue et al. 2000
). The fact that this polypeptide is immunopurified by multiple PBAF antibodies strongly suggests that it could be a new component of PBAF.
To obtain large amounts of BAF200 for identification, we used an improved immunoprecipitation (IP) protocol to directly isolate PBAF from HeLa nuclear extract using an antibody against BAF180 (the previous purification used 0.75 M phosphocellulose fraction of HeLa nuclear extract). The purity of PBAF complex isolated by the new protocol is comparable to that obtained by the previous method (Fig. 1A), and a 200-kDa polypeptide (BAF200) was similarly detected. This polypeptide was identified by mass spectrometry as a hypothetical protein of 1835 amino acid residues, with the approved gene symbol of ARID2 (AT-rich interactive domain 2; aliases: KIAA1557, DKFZp686G052, FLJ30619 gene accession ID: NP_689854 [GenBank] ).
We also used mass spectrometry to analyze the 200-kDa polypeptide in the PBAF complex immunoisolated by the Flag antibody from HeLa cells stably expressing Flag-tagged hSNF5/INI1 as described (Xue et al. 2000
). The results confirmed that this polypeptide is ARID2. The findings that ARID2 is present in PBAF immunopurified by two independent antibodies indicate that it is an integral component of PBAF. A polyclonal antibody raised against ARID2 also specifically recognized the 200-kDa polypeptide in the PBAF complex isolated by antibodies to either BAF180 or Flag-hSNF5 (Fig. 1B,C), providing further confirmation for ARID2 as BAF200.
|
We also analyzed the Superose 6 gel-filtration profile of BAF200 in HeLa nuclear extract, and compared it with that of other BAF proteins. The results showed that the profile of BAF200 was identical to that of the PBAF-specific subunit, BAF180, which supports the notion that these two proteins are unique components of the PBAF complex (Fig. 1D). As a comparison, the profiles of BAF200 and BAF180 only partially overlapped with those of BRG1, BAF57, and hSNF5. Because the latter three proteins are shared by many other SWI/SNF complexes (including BAF, which is more abundant than PBAF), it is not too surprising that their profiles are different from those of BAF200 and BAF180.
The expression of BAF200 mRNA was detected by Northern blot analysis in multiple human tissues that have been examined (data not shown). This property resembles that of BAF180, as well as some other BAF genes.
BAF200 is a new specificity subunit of PBAF and absent in BAF
In our previously purified PBAF and BAF complexes from fractionated HeLa nuclear extract, BAF200 was detected only in PBAF, but not BAF, by silver-stained SDS-gel analysis (Nie et al. 2000
; Xue et al. 2000
). To exclude the possibility that BAF200 may also be a subunit of BAF complex but was dissociated during fractionation of HeLa nuclear extract, we directly immunoisolated PBAF and BAF from unfractionated extract under mild washing conditions (0.3 M salt) using either BAF180 (PBAF) or BAF250a (BAF) antibodies, respectively. Consistent with previous data, BAF200 was detected in only PBAF, but not BAF (Fig. 1E).
We also performed reciprocal IP to determine whether BAF200-associated polypeptides contain PBAF or BAF components. Because our BAF200 antibody was inefficient in IP (data not shown), we established a HeLa cell line stably expressing BAF200 tagged with a Flag epitope. The BAF200-associated polypeptides immunoisolated by the Flag antibody contained the PBAF-specific subunit, BAF180, but not the BAF-specific subunit, BAF250a (Fig. 1F), consistent with the data above that BAF200 is a new specific subunit of PBAF complex. The polypeptides also included components that are shared by many SWI/SNF complexes, such as BRG1, BAF170, BAF155, BAF57, and hSNF5/INI1. As a control, mock IP using nuclear extract from HeLa cells that do not express Flag-BAF200 yielded no PBAF components. Taken together, our data demonstrate that BAF200, like BAF180, is a specific subunit of the PBAF complex.
BAF200, but not BAF180, is essential for the stability of PBAF complex in vivo
Previous studies have shown that the absence of certain yeast SWI/SNF subunits results in reduced stability of other SWI/SNF components, suggesting that these subunits may be critical for the assembly of the complex (Peterson et al. 1994
). We examined the role of BAF200 in PBAF assembly by siRNA knockdown. Depletion of BAF200 in HeLa cells by either siRNA oligos (Fig. 2A) or a vector-based siRNA (Fig. 2B) resulted in not only reduced level of BAF200, but also that of BAF180. As a comparison, depletion of BAF200 had no significant effect on the level of other PBAF subunits that are shared with the BAF complex. Because BAF180 is the only defining subunit of the PBAF complex other than BAF200 (Xue et al. 2000
; Lemon et al. 2001
), our results suggest that BAF200 is essential for the stability of PBAF complex in vivo, perhaps by recruiting BAF180 into the complex.
We also knocked down BAF180 by siRNA in HeLa cells and found that the level of BAF200 was comparable to cells treated with a scrambled control oligo (Fig. 2C). Moreover, a breast cancer cell line (HCC1143) with a biallelic mutation in the BAF180 gene and an undetectable level of BAF180 protein (R. Parsons, unpubl.) expressed BAF200 at a level indistinguishable to that of HeLa and another breast cancer cell line MCF7 (Fig. 2D), suggesting that BAF180 is dispensable for the stability of BAF200, and may also be dispensable for assembly of BAF200 into PBAF (see below).
BAF200 is a homolog of Drosophila BAP170 and contains several conserved domains
A search of the GenBank database revealed that BAF200 (ARID2) has sequence orthologs in mouse, chicken (Gallus gallus), Drosophila, Anopheles gambiae, and Caenorhabditis elegans, but not in yeast. The C. elegans ortholog of BAF200 (NP_495679
[GenBank]
) has been analyzed by a genome-wide siRNA study, and found to be essential for embryonic development (Kamath et al. 2003
). Its Drosophila ortholog, BAP170, was recently identified as a component of the PBAP chromatin-remodeling complex (Mohrmann et al. 2004
). Drosophila has two SWI/SNF-related complexes, BAP and PBAP, which appear to correspond to human BAF and PBAF, respectively. Both BAP170 and a fly homolog of BAF180 (Polybromo) were identified as the defining subunits for PBAP, whereas a homolog of BAF250a (Osa) is the defining subunit for BAP. The fact that BAF200 and its homolog are defining subunits in both human PBAF and Drosophila PBAP complexes suggests that these proteins may have conserved functions.
|
PBAF and BAF are selectively required for expression of distinct IFN-
-inducible genes
SWI/SNF complexes were shown to directly regulate expression of multiple interferon-responsive genes, based on chromatin-IP and other studies (Agalioti et al. 2002
; Huang et al. 2002
; Liu et al. 2002
; Pattenden et al. 2002
; Cui et al. 2004
). However, because these results are based on analyses of subunits that are shared among various SWI/SNF complexes, it remains unclear which complex (BAF or PBAF) participates in such regulation. We attempted to make this distinction by depleting the subunits uniquely present in BAF or PBAF, which should inactivate only their corresponding complex but not the other. Between the two unique subunits of PBAF (BAF180 and BAF200), we first chose to deplete BAF200 because its loss also triggers concomitant destabilization of BAF180 (Fig. 2A,B). Thus, depletion of BAF200 could lead to complete inactivation of PBAF.
We screened eight SWI/SNF-dependent interferon-
-inducible genes (Liu et al. 2002
; Cui et al. 2004
) in HeLa cells that were stably knocked down of BAF200 by a vector-based siRNA (Fig. 2B). Induction of the IFITM1 gene was strongly inhibited (Fig. 3A). The same result was also observed when BAF200 was knocked down by two different siRNA oligos (Fig. 3B). Notably, the induction of this gene remains undisturbed in HeLa cells depleted of BAF250a, the BAF-specific subunit (Fig. 3C,D). These results indicate that IFITM1 gene expression specifically depends on PBAF but not BAF.
|
-inducible genes that depend on BAF but not PBAF. We noticed that the expression levels of IFITM3 gene under basal and IFN-
-induced conditions were largely unaffected in HeLa cells depleted of BAF200 by vector-based siRNA (Fig. 3A), suggesting that expression of this gene is PBAF-independent, and may be dependent on other SWI/SNF complexes, such as BAF. Further analysis revealed that IFITM3 gene expression under both basal and IFN-
-induced conditions was strongly inhibited in HeLa cells depleted of BAF250a by siRNA oligos (Fig. 3C), but remained unaltered in cells depleted of BAF200 by siRNA oligos (Fig. 3B). These data demonstrate that although IFITM1 and IFITM3 are both IFN-
-inducible genes, they depend on distinct SWI/SNF complexes for optimal expression: The IFITM1 gene is PBAF-dependent, whereas IFITM3 is BAF-dependent.
The PBAF-specific subunit BAF180 is dispensable for IFITM1 gene expression
We found that knocking down BAF180 in HeLa cells by two different siRNA oligos (Fig. 2C) had no significant effect on induction of the IFITM1 gene by IFN-
(Fig. 4A). This is somewhat surprising because BAF180 is also a specific subunit of PBAF complex (Xue et al. 2000
), and has been shown to be essential for expression of several genes (Wang et al. 2004
). One possible explanation is that BAF180 was not completely removed by siRNA, so that the residual amount of this protein is still able to mediate induction of the IFITM1 gene. To address this possibility, we analyzed IFITM1 gene induction in the BAF180-deficient cell line HCC1143, and the same cell line stably expressing ectopically introduced BAF180 (Fig. 4B). The results show that IFITM1 gene induction was normal in the HCC1143 cells, and this induction was unaffected by reintroduction of BAF180 into these cells (Fig. 4C). These results suggest that the expression of the IFITM1 gene is independent of BAF180.
BAF200 forms a complex in the absence of BAF180 and mediates the expression of the IFITM1 gene
The data above showed that in both BAF180-depleted HeLa cells and BAF180-deficient HCC1143 cells, the expression of BAF200 remains normal (Fig. 2C,D), which correlates with the normal induction of the IFITM1 gene (Fig. 4A,C), implying that BAF200 may be able to form a complex in the absence of BAF180 that mediates induction of IFITM1 and perhaps other genes. Consistent with this notion, BAF200 from the extract of HCC1143 cells cofractionated with PBAF subunits BRG1 and BAF57 in a complex of near 1 MDa by Superose 6 gel-filtration chromatography (Fig. 5A). The peak of BAF200 was shifted only two fractions compared with that of HeLa (from 18 to 20) (cf. Fig. 1D), hinting that a significant portion of PBAF complex remains intact without BAF180. Indeed, BAF200 from HCC1143 extract coimmunoprecipitated with BRG1 and BAF57 (Fig. 5B). Biochemical purification of PBAF from HCC1143 cells (Fig. 5C) revealed that it has nearly all the components as the PBAF from HeLa cells, including BAF200, BRG1, and other subunits (Fig. 5D). One important difference is that it lacks BAF180, but contains a novel polypeptide with similar molecular weight as BAF180 (marked with an asterisk). This polypeptide is not BAF180 based on immunoblotting (data not shown), and its relevance to PBAF function is under investigation. Nevertheless, these data together demonstrate that BAF200 can form a new version of PBAF complex absent of BAF180.
The immediate question is whether this complex is still functional. Suppression of BAF200 by siRNA in HCC1143 cells (Fig. 5E) reduced IFITM1 gene expression at both basal and IFN-
-induced levels (Fig. 5F), which is similar to the data from HeLa cells (cf. Fig. 3B). The results suggest that this new version of PBAF is still functional and capable of mediating the IFITM1 gene expression.
|
|
How is each complex directed to its correct target genes? Because the human BAF and PBAF share the majority of their subunits, their targeting should be accomplished primarily through the specificity subunits that distinguish them. Here we show that PBAF has a second specificity subunit, BAF200, which possesses several conserved domains that are distinct from those in BAF180. It is therefore conceivable that these different domains in BAF200 and BAF180 can target PBAF to different genes through proteinprotein or proteinDNA interactions. Consistent with this notion, we show that BAF200 is essential for expression of the IFITM1 gene, whereas BAF180 is not, indicating that at least for this gene, the targeting subunit should be BAF200, but not BAF180. On the other hand, mice inactivated of BAF180 have been found to display severe defects in cardiac chamber maturation, and BAF180 is required for normal expression of several important genes (Wang et al. 2004
), suggesting that in the latter case, the targeting subunit could be BAF180. However, it remains possible that BAF200 is also the essential targeting subunit for the latter genes, wherein BAF180 plays an essential but non-targeting role. Distinguishing these possibilities would require inactivating BAF200 without interfering with other subunits of PBAF. This will be difficult because complete elimination of BAF200 results in concomitant destabilization of BAF180. One therefore has to create specific mutants in BAF200 that eliminate its targeting function, but do not destabilize BAF180. Nevertheless, our study suggests that genes that require BAF180 for expression represent only a subset of PBAF-dependent genes, and a complete account of all PBAF-dependent genes will require identification of those that require BAF200 for expression.
| Materials and methods |
|---|
|
|
|---|
PBAF complex was directly immunoisolated with a BAF180 antibody from HeLa nuclear extract by using an IP protocol as described (Xue et al. 2003
). Before IP, the extract was incubated with or without ethidium bromide (EtBr, 100 µg/mL) for 1 h. The PBAF complex was purified from Flag-hSNF5/INI1 cells as described (Xue et al. 2000
). The superpose 6 gel-filtration analysis has been described (Xue et al. 2000
). The band corresponding to 200 kDa on the Coomassie blue-stained SDS gel was excised and subjected to mass spectrometric analysis as described (Xue et al. 2003
). A cDNA clone (PR1374_A05) encoding the large part of this protein (ARID2) was purchased from OriGene, Inc. The missing sequence was generated by PCR using another cDNA clone (AB2553_E11) from OriGene as a donor, and the two fragments were assembled into the cDNA with a full-length open reading frame.
siRNA experiment
For vector-based siRNA, HeLa cells were transfected with either the BAF200 siRNA construct (Supplemental Material) or a control vector by using Superfect (QIAGEN), and selected in 1 µg/mL of puromycin for 5 d. The remaining cells were then extracted with a lysis buffer (10 mM Tris-HCl at pH 7.5, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, 300 mM NaCl, 1 mM EDTA) and subsequently analyzed by immunoblotting. Sometimes, cells were treated with IFN-
(500 U/mL) for 8 h prior to harvest. For oligonucleotide-based siRNA, HeLa or HCC1143 cells were transfected with the different siRNA oligos (Supplemental Material) by using Oligofectamine (Invitrogen). After 2 d, the cells were lyzed for immunoblotting, or treated with IFN-
(500 U/mL) for 8 h followed by RTPCR analysis as described (Liu et al. 2001
).
Other experimental procedures are described in the Supplemental Material.
| Acknowledgments |
|---|
|
|
|---|
| Footnotes |
|---|
Article published online ahead of print. Article and publication date are at http://www.genesdev.org/cgi/doi/10.1101/gad.1323805.
E-MAIL wangw{at}grc.nia.nih.gov; FAX (410) 558-8331. ![]()
| References |
|---|
|
|
|---|
Angus-Hill, M.L., Schlichter, A., Roberts, D., Erdjument-Bromage, H., Tempst, P., and Cairns, B.R. 2001. A Rsc3/Rsc30 zinc cluster dimer reveals novel roles for the chromatin remodeler RSC in gene expression and cell cycle control. Mol. Cell 7: 741751.[CrossRef][Medline]
Cairns, B.R., Kim, Y.J., Sayre, M.H., Laurent, B.C., and Kornberg, R.D. 1994. A multisubunit complex containing the SWI1/ADR6, SWI2/SNF2, SWI3, SNF5, and SNF6 gene products isolated from yeast. Proc. Natl. Acad. Sci. 91: 19501954.
Cairns, B.R., Lorch, Y., Li, Y., Zhang, M., Lacomis, L., Erdjument-Bromage, H., Tempst, P., Du, J., Laurent, B., and Kornberg, R.D. 1996. RSC, an essential, abundant chromatin-remodeling complex. Cell 87: 12491260.[CrossRef][Medline]
Cote, J., Quinn, J., Workman, J.L., and Peterson, C.L. 1994. Stimulation of GAL4 derivative binding to nucleosomal DNA by the yeast SWI/SNF complex. Science 265: 5360.
Cui, K., Tailor, P., Liu, H., Chen, X., Ozato, K., and Zhao, K. 2004. The chromatin-remodeling BAF complex mediates cellular antiviral activities by promoter priming. Mol. Cell. Biol. 24: 44764486.
Gajiwala, K.S. and Burley, S.K. 2000. Winged helix proteins. Curr. Opin. Struct. Biol. 10: 110116.[CrossRef][Medline]
Hamiche, A., Sandaltzopoulos, R., Gdula, D.A., and Wu, C. 1999. ATP-dependent histone octamer sliding mediated by the chromatin remodeling complex NURF. Cell 97: 833842.[CrossRef][Medline]
Huang, M., Qian, F., Hu, Y., Ang, C., Li, Z., and Wen, Z. 2002. Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-
-inducible genes. Nat. Cell Biol. 4: 774781.[CrossRef][Medline]
Kamath, R.S., Fraser, A.G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, A., Le Bot, N., Moreno, S., Sohrmann, M., et al. 2003. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421: 231237.[CrossRef][Medline]
Kornberg, R.D. and Lorch, Y. 1999. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98: 285294.[CrossRef][Medline]
Kwon, H., Imbalzano, A.N., Khavari, P.A., Kingston, R.E., and Green, M.R. 1994. Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature 370: 477481.[CrossRef][Medline]
Lemon, B., Inouye, C., King, D.S., and Tjian, R. 2001. Selectivity of chromatin-remodelling cofactors for ligand-activated transcription. Nature 414: 924928.[CrossRef][Medline]
Levine, M. and Tjian, R. 2003. Transcription regulation and animal diversity. Nature 424: 147151.[CrossRef][Medline]
Liu, R., Liu, H., Chen, X., Kirby, M., Brown, P.O., and Zhao, K. 2001. Regulation of CSF1 promoter by the SWI/SNF-like BAF complex. Cell 106: 309318.[CrossRef][Medline]
Liu, H., Kang, H., Liu, R., Chen, X., and Zhao, K. 2002. Maximal induction of a subset of interferon target genes requires the chromatin-remodeling activity of the BAF complex. Mol. Cell. Biol. 22: 64716479.
Lorch, Y., Zhang, M., and Kornberg, R.D. 1999. Histone octamer transfer by a chromatin-remodeling complex. Cell 96: 389392.[CrossRef][Medline]
Mohrmann, L., Langenberg, K., Krijgsveld, J., Kal, A.J., Heck, A.J., and Verrijzer, C.P. 2004. Differential targeting of two distinct SWI/SNF-related Drosophila chromatin-remodeling complexes. Mol. Cell. Biol. 24: 30773088.
Nie, Z., Xue, Y., Yang, D., Zhou, S., Deroo, B.J., Archer, T.K., and Wang, W. 2000. A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol. Cell. Biol. 20: 88798888.
Papoulas, O., Beek, S.J., Moseley, S.L., McCallum, C.M., Sarte, M., Shearn, A., and Tamkun, J.W. 1998. The Drosophila trithorax group proteins BRM, ASH1 and ASH2 are subunits of distinct protein complexes. Development 125: 39553966.[Abstract]
Pattenden, S.G., Klose, R., Karaskov, E., and Bremner, R. 2002. Interferon-
-induced chromatin remodeling at the CIITA locus is BRG1 dependent. EMBO J. 21: 19781986.[CrossRef][Medline]
Peterson, C.L., Dingwall, A., and Scott, M.P. 1994. Five SWI/SNF gene products are components of a large multisubunit complex required for transcriptional enhancement. Proc. Natl. Acad. Sci. 91: 29052908.
Savkur, R.S. and Burris, T.P. 2004. The coactivator LXXLL nuclear receptor recognition motif. J. Pept. Res. 63: 207212.[CrossRef][Medline]
Vignali, M., Hassan, A.H., Neely, K.E., and Workman, J.L. 2000. ATP-dependent chromatin-remodeling complexes. Mol. Cell. Biol. 20: 18991910.
Wang, W., Cote, J., Xue, Y., Zhou, S., Khavari, P.A., Biggar, S.R., Muchardt, C., Kalpana, G.V., Goff, S.P., Yaniv, M., et al. 1996. Purification and biochemical heterogeneity of the mammalian SWISNF complex. EMBO J. 15: 53705382.[Medline]
Wang, Z., Zhai, W., Richardson, J.A., Olson, E.N., Meneses, J.J., Firpo, M.T., Kang, C., Skarnes, W.C., and Tjian, R. 2004. Polybromo protein BAF180 functions in mammalian cardiac chamber maturation. Genes & Dev. 18: 31063116.
Whitehouse, I., Flaus, A., Cairns, B.R., White, M.F., Workman, J.L., and Owen-Hughes, T. 1999. Nucleosome mobilization catalysed by the yeast SWI/SNF complex. Nature 400: 784787.[CrossRef][Medline]
Xue, Y., Canman, J.C., Lee, C.S., Nie, Z., Yang, D., Moreno, G.T., Young, M.K., Salmon, E.D., and Wang, W. 2000. The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc. Natl. Acad. Sci. 97: 1301513020.
Xue, Y., Gibbons, R., Yan, Z., Yang, D., McDowell, T.L., Sechi, S., Qin, J., Zhou, S., Higgs, D., and Wang, W. 2003. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc. Natl. Acad. Sci. 100: 1063510640.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
I. Carrera, J. Zavadil, and J. E. Treisman Two Subunits Specific to the PBAP Chromatin Remodeling Complex Have Distinct and Redundant Functions during Drosophila Development Mol. Cell. Biol., September 1, 2008; 28(17): 5238 - 5250. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Chalkley, Y. M. Moshkin, K. Langenberg, K. Bezstarosti, A. Blastyak, H. Gyurkovics, J. A. A. Demmers, and C. P. Verrijzer The Transcriptional Coactivator SAYP Is a Trithorax Group Signature Subunit of the PBAP Chromatin Remodeling Complex Mol. Cell. Biol., May 1, 2008; 28(9): 2920 - 2929. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yan, Z. Wang, L. Sharova, A. A. Sharov, C. Ling, Y. Piao, K. Aiba, R. Matoba, W. Wang, and M. S. H. Ko BAF250B-Associated SWI/SNF Chromatin-Remodeling Complex Is Required to Maintain Undifferentiated Mouse Embryonic Stem Cells Stem Cells, May 1, 2008; 26(5): 1155 - 1165. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Xia, S. Nagase, A. G. Montia, S. M. Kalachikov, M. Keniry, T. Su, L. Memeo, H. Hibshoosh, and R. Parsons BAF180 Is a Critical Regulator of p21 Induction and a Tumor Suppressor Mutated in Breast Cancer Cancer Res., March 15, 2008; 68(6): 1667 - 1674. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Trotter, H.-Y. Fan, M. L. Ivey, R. E. Kingston, and T. K. Archer The HSA Domain of BRG1 Mediates Critical Interactions Required for Glucocorticoid Receptor-Dependent Transcriptional Activation In Vivo Mol. Cell. Biol., February 15, 2008; 28(4): 1413 - 1426. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. M. Moshkin, L. Mohrmann, W. F. J. van Ijcken, and C. P. Verrijzer Functional Differentiation of SWI/SNF Remodelers in Transcription and Cell Cycle Control Mol. Cell. Biol., January 15, 2007; 27(2): 651 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ni and R. Bremner Brahma-Related Gene 1-Dependent STAT3 Recruitment at IL-6-Inducible Genes J. Immunol., January 1, 2007; 178(1): 345 - 351. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||